New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:06 EDTPATH, ENDP, TEVANuPathe terminates agreement with Endo, to be acquired by Teva
NuPathe (PATH) announced that it has terminated its agreement and plan of merger with Endo Health Solutions (ENDP) and its board has withdrawn its recommendation that stockholders accept Endo's offer to acquire all outstanding shares of NuPathe common stock. NuPathe has also entered into an agreement and plan of merger with Teva Pharmaceutical (TEVA) under which Teva will acquire NuPathe for $3.65 per share in cash. In addition to the upfront cash payment, NuPathe stockholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, Zecuity, are achieved over time. Under the terms of the agreement, an affiliate of Teva will promptly commence a tender offer to acquire all outstanding shares of NuPathe's common stock for $3.65 per share in cash and the right to receive contingent cash consideration payments of up to $3.15 per share if specified net sales thresholds for NuPathe's Zecuity are achieved. The contingent cash consideration payments, which will not be publicly traded, are as follows: $2.15 per share in cash payable upon net sales of Zecuity of at least $100M in any four consecutive calendar quarters, on or prior to the 60th day following the ninth anniversary of the date of the first commercial sale of Zecuity; and $1.00 per share in cash payable upon net sales of ZECUITY of at least $300 million in any four consecutive calendar quarters, on or prior to the 60th day following the ninth anniversary of the date of the first commercial sale of Zecuity. The transaction is expected to be completed in February.
News For PATH;ENDP;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:11 EDTTEVATeva reported great Q3 results, says BMO Capital
Subscribe for More Information
09:06 EDTTEVATeva says assessing M&A opportunities of all sizes
08:49 EDTTEVATeva says may pursue generic businesses in emerging markets
Says not ruling out "transformational" transactions. Says open to specialty assets in U.S., Europe.
08:40 EDTTEVATeva says $5.00-$5.10 FY14 EPS guidance is for exclusive Copaxone scenario
Subscribe for More Information
07:06 EDTTEVATeva board authorizes increase in share repurchase program to $3B
The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.
07:05 EDTTEVATeva raises FY14 EPS view to $5.00-$5.10 from $4.90-$5.10
Subscribe for More Information
07:05 EDTTEVATeva reports Q3 EPS $1.32, consensus $1.23
Subscribe for More Information
October 27, 2014
07:22 EDTTEVAAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 23, 2014
10:01 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTENDPEndo initiated with a Buy at Guggenheim
Subscribe for More Information
October 21, 2014
06:37 EDTENDPEndo pullback brings buying opportunity, says Piper Jaffray
Subscribe for More Information
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use